ViiV Healthcare Company

Founded in 2002, Chimerix is a privately held biotechnology company that creates and develops orally available medicines from bioactive molecules. Its applications of proprietary technology enhance oral availability, stabilize drug in plasma and facilitates the delivery of drugs into targeted tissues. Chimerix offers drugs that can be modified to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Its technology also enables discovery of new drugs from molecules with chemical properties that would otherwise be unsuitable for pharmaceutical development. In addition, Chimerix applies its technology towards discovery and the development of oral drugs for the treatment of smallpox, drug-resistant HIV infection and viral hepatitis. The company is located in Durham, N.C.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatment for people with life-threatening disorders. The company s wholly owned subsidiary, Talecris Plasma Resources, is a national network of plasma collection centers that provides the source material for the production of critical care protein therapies. Talecris Biotherapeutics employs more than 4,300 people worldwide. The company is licensed to do in-house nucleic acid testing for hepatitis C, hepatitis B and human immunodeficiency virus. It offers aseptic filling, plasma fractionation and pharmaceutical compounding, as well as extraction, concentration and purification services for complex molecules. Talecris Biotherapeutics sponsors external research grant programs.

Evecxia Therapeutics, Inc., based in Durham, NC, is a pioneering pharmaceutical company dedicated to improving the lives of individuals with mental illness. With a focus on serotonin synthesis amplification, Evecxia is at the forefront of developing innovative drug delivery technologies to harness the therapeutic potential of 5-hydroxytryptamine (5-HTP), the natural precursor of serotonin. By amplifying the production of natural brain serotonin, Evecxia aims to provide more effective treatment options for individuals suffering from mental illnesses that are not adequately addressed by current therapies. Driven by the mission to help individuals lead fuller and more meaningful lives, Evecxia Therapeutics is committed to addressing the negative impact of mental illness on various aspects of life, including emotional well-being, work performance, and relationships. By leveraging their expertise in serotonin neurotransmission, Evecxia is developing novel drug candidates that have shown promise in clinical settings, particularly as adjunctive therapies for depression. Through their innovative approach, Evecxia Therapeutics aims to revolutionize the treatment of mental illnesses and provide new hope for those in need.Generated from the website